Floatz logo

Pomalidomide

Plasmablastic Lymphoma

National Cancer Institute (NCI)Small moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

23 Active assets in the Plasmablastic Lymphoma cohort.

Asset / SponsorPhaseRating
Inno-206
National Cancer Institute (NCI)
Phase 2BB
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 2BB
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BB
(+)-VINCRISTINE
National Cancer Institute (NCI)
Phase 2BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2BB

View all 27 →

Same molecule, other indications

Pomalidomide is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
67 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
63 / 100
View asset →
AmyloidosisDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →